All posts by: Michael Zand

About Michael Zand

After a unanimous panel vote, will Spark’s novel gene therapy be a $1 million drug? – STAT

Continue reading

2017-10-12 NEWS

STAT

After a unanimous panel vote, will Spark’s novel gene therapy be a $1 million drug?
STAT
If the panel votes yes and the FDA follows its recommendation, Luxturna would become the first therapy meant to replace or repair a defective gene approved in the U.S. Spark hasn’t disclosed pricing, but analysts estimate Luxturna could cost $1 million